OFFICIALS LEGISLATION INTEREST GROUPS PUBLIC STATEMENTS COMMITTEES VETOES

Making Objective Drug Evidence Revisions for New Labeling Act of 2020

Floor Speech

Date: Nov. 17, 2020
Location: Washington, DC

BREAK IN TRANSCRIPT

Mr. GUTHRIE. Mr. Speaker, I thank the ranking member for yielding.

I appreciate working with the chairman and with everyone involved in this piece of legislation.

I rise today to voice my support for H.R. 5668, the MODERN Labeling Act of 2020. This important bill will ensure that certain drug labels are updated and accurate, which will result in better care for many Americans who are suffering. This bill grants FDA the authority to work with generic drug companies to update their product label when there are strong, scientific bases for another indication or use of the drug.

Innovation in America is constantly evolving, and we must ensure drug labels are updated and not frozen in time just because the brand-name drug is off the market and preventing the generic drug from updating its label.

I would like to thank Representative Matsui, Chairman Pallone, and the majority and minority Energy and Commerce Committee staff who worked with me to make this legislation possible.

I urge my colleagues to support this important bill.

BREAK IN TRANSCRIPT


Source
arrow_upward